Trials / Completed
CompletedNCT03371836
Use of Clobazam for Epilepsy and Anxiety
Use of Clobazam in Treating Anxiety Comorbid With Pediatric Epilepsy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc. · Academic / Other
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open label, adjunctive, proof of concept, pilot clinical trial. Pediatric patients with epilepsy and clinically significant anxiety will be recruited and if enrolled will receive active treatment, involving flexible dose titration of clobazam and will be monitored for a period of four months. The study will be monitored and overseen by the Johns Hopkins Hospital Institutional Review Board.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clobazam | Clobazam is used as an adjunct medicine for all participants. |
Timeline
- Start date
- 2017-10-01
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
- First posted
- 2017-12-13
- Last updated
- 2021-03-04
- Results posted
- 2021-03-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03371836. Inclusion in this directory is not an endorsement.